Why Has Chelsea Therapeutics International Ltd.(NASDAQ:CHTP) Interests AstraZeneca Plc.


Dallas, Texas 03/18/2014 (FINANCIALSTRENDS) –  Chelsea Therapeutics International Ltd.(NASDAQ:CHTP) is an interesting drug maker in mainstream biotechnology sector, which holds promise for the giant drug marketing companies such as AstraZeneca and Eli Lilly.

Reasons which CHTP is important in the current pileup

Chelsea Therapeutics International Ltd.(NASDAQ:CHTP) and others of its ilk, which are typically small-sized in structure and hold pipelines or new drugs, are just the treatment which the doctor prescribed for the giant drug marketers that AstraZeneca Plc and Eli Lilly are.

As the big players on the crowded pharmaceutical industry arrive at a -patent cliff- the tectonic shift in this globally thriving industry is set to change.

Both Astra Zeneca and Eli Lilly have their high net worth drugs now completing their patent protection hiatus.

Therefore, most of the bigwigs which will lose out on the big bucks are looking to line their product kitties, with bite-sized companies which do not require intense investment to Buyout, and also have a stockpile, which will allow them to see the previous high returns at the turnstile.

Operation Buyouts

Chelsea Therapeutics International Ltd.(NASDAQ:CHTP) and other interesting small-sized company – InterMune Inc (NASDAQ:ITMN) are currently top-two in the list of Buyouts pharma majors’ are drawing for the year 2014.

Chelsea holds added attraction, because of its orphan drug – Northera. This drug is used to treat symptoms and manifestation of conditions such as dizziness, typically caused when patients are being treated for conditions related to NOH or Neurogenic Orthostatic Hypotension.

Northera holds the distinction of being one of the first drugs to have been endorsed by the Food and Drug Administration in the US.

Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) however, has a downside which has nothing to do with the efficacy of Northera- NOH is currently not one of the easily diagnosed conditions in the country. This means the drug’s overall use-base is undefined, though analysts do name figures in the region of $300 million to $450 million in sale of Northera.